English, Article edition: Association between Abciximab and Length of Stay in Intensive Care for Patients Undergoing Percutaneous Coronary Intervention: A 2-Stage Econometric Model in a Naturalistic Setting Maureen J. Lage; Beth L. Barber; Mohan Bala; ...

User activity

Share to:
 
Bookmark: http://trove.nla.gov.au/version/118955
Physical Description
  • article
Language
  • English

Edition details

Title
  • Association between Abciximab and Length of Stay in Intensive Care for Patients Undergoing Percutaneous Coronary Intervention: A 2-Stage Econometric Model in a Naturalistic Setting
Author
  • Maureen J. Lage
  • Beth L. Barber
  • Mohan Bala
  • Patrick L. McCollam
  • Daniel E. Ball
Physical Description
  • article
Notes
  • Objective: To examine the effect of abciximab treatment on intensive care length of stay for patients undergoing percutaneous coronary intervention (PCI). Design and setting: A retrospective study conducted in a naturalistic setting. Methods: A 2-stage econometric model was used to control for the influence of possible selection bias across categories of patients and for both observable and unobservable factors correlated with each patient's treatment selection and length of stay in intensive care. Multivariate analysis was applied to control for a wide range of factors (patient demographics, insurance provider, health conditions, admission and discharge information, and hospital characteristics) that may influence intensive care length of stay. Retrospective data were obtained from HCIA's Clinical Pathways Database. Participants: Patients (n =​ 13 364) who were hospitalised in any of 87 hospitals across the US over the period from October 1, 1995 to December 1, 1996. Results: After controlling for high-risk indications and selection bias, results indicated that administration of abciximab was associated with a significantly shorter length of stay in intensive care compared with not administering a GPIIb/​ IIIa inhibitor (0.45 fewer days; p <=​ 0.0001). In a subgroup analysis of patients having an acute myocardial infarction (n =​ 4793), administration of abciximab was also associated with a significantly shorter intensive care stay (0.27 fewer days; p < 0.0001). Conclusion: Results of this study indicate that the administration of abciximab is associated with a reduction in the length of stay in intensive care. This reduction implies potential cost offsets for patients undergoing PCI who receive abciximab.
  • Abciximab, Angioplasty, Antianginals, Coronary disorders, Cost analysis, Intensive care units, Pharmacoeconomics
  • RePEc:wkh:phecon:v:18:y:2000:i:6:p:581-589
Language
  • English
Contributed by
OAIster

Get this edition

  • Set up My libraries

    How do I set up "My libraries"?

    In order to set up a list of libraries that you have access to, you must first login or sign up. Then set up a personal list of libraries from your profile page by clicking on your user name at the top right of any screen.

  • All (1)
  • Unknown (1)
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.

User activity


e.g. test cricket, Perth (WA), "Parkes, Henry"

Separate different tags with a comma. To include a comma in your tag, surround the tag with double quotes.

Be the first to add a tag for this edition

Be the first to add this to a list

Comments and reviews

What are comments? Add a comment

No user comments or reviews for this version

Add a comment